International Stem Cell Corporation is Valued at $34 Million Market Value by Edison Investment Research
May 14 2018 - 8:30AM
InvestorsHub NewsWire
CARLSBAD, CA -- May 14, 2018 -- InvestorsHub
NewsWire -- International Stem Cell Corporation (OTCQB:ISCO)
("ISCO" or "the Company"), a California-based clinical stage
biotechnology company developing novel stem cell-based therapies
and biomedical products, announced today that it has been valued at
$34 million, up from $33 million in January 2018, by Edison
Investment Research ("Edison")*, a world-renowned investment
intelligence firm with more than one hundred analysts, investment
experts, and roadshow professionals, with offices in North America,
Europe, the Middle East and Asia.
The research report is available on Edison's
website and can be accessed here.
The report features an analysis of ISCO's financial data, along
with an investment summary that showcases the Company's cell
therapy for Parkinson's disease and traumatic brain injury as key
industry differentiators.
The summary discusses the completion of ISCO’s
dosing of its second cohort in its Phase I trial of ISC-hpNSC in
Parkinson’ disease and its preparation to commence a Phase II trial
in 2018. The open-label, single-center (at Royal Melbourne Hospital
in Melbourne, Australia) is an uncontrolled clinical trial that
evaluates three different dose regimens of 30m, 50m, and 70m cells.
A total of 12 participants with moderate-to-severe Parkinson’s
disease are to be enrolled. Patients are monitored to evaluate the
safety and biologic activity of ISC-hpNSC for one
year.
ISCO has also completed preclinical studies of
ISC-hpNSC in traumatic brain injury and was preparing to commence a
Phase II trial, which is also expected to launch later this year.
Once Phase II data in TBI are in hand, Edison expects ISCO to apply
to the FDA for the new Regenerative Medicine Advanced Therapy
(RMAT) designation, which came into existence as part of the 21st
Century Cures Act.
Edison claims that traumatic brain injury could be
as meaningful to the company as Parkinson’s disease, for which they
are forecasting $2.8bn in peak sales.
And in addition to a significant reduction in cash
burn, ISCO also reported revenues of $7.5 million, up 4.1% compared
to 2016.
About International Stem Cell
Corporation
International Stem Cell Corporation is focused on
the therapeutic applications of human parthenogenetic stem cells
(hpSCs) and the development and commercialization of cell-based
research and cosmetic products. ISCO's core technology,
parthenogenesis, results in the creation of pluripotent human stem
cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues
associated with the use or destruction of viable human embryos.
ISCO scientists have created the first parthenogenetic, homozygous
stem cell line that can be a source of therapeutic cells for
hundreds of millions of individuals of differing genders, ages and
racial background with minimal immune rejection after
transplantation. hpSCs offer the potential to create the first true
stem cell bank, UniStemCell™. ISCO also produces and markets
specialized cells and growth media for therapeutic research
worldwide through its subsidiary Lifeline Cell Technology
(www.lifelinecelltech.com), and stem cell-based skin care products
through its subsidiary Lifeline Skin Care (www.lifelineskincare.com).
More information is available
at www.internationalstemcell.com.
To
subscribe to receive ongoing corporate communications, please click
on the following link:
http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0
To
like our Facebook page or follow us on Twitter for company updates
and industry related news, visit:
www.facebook.com/InternationalStemCellCorporation
and www.twitter.com/intlstemcell
*The Edison report was sponsored by the
Company.
Safe harbor
statement
Statements pertaining to anticipated developments,
expected pre-clinical studies (including timing and results),
progress of research and development, and other opportunities for
the company and its subsidiaries, along with other statements about
the future expectations, beliefs, goals, plans, or prospects
expressed by management constitute forward-looking statements. Any
statements that are not historical fact (including, but not limited
to statements that contain words such as "will," "believes,"
"plans," "anticipates," "expects," "estimates,") should also be
considered to be forward-looking statements. Forward-looking
statements involve risks and uncertainties, including, without
limitation, risks inherent in the development and/or
commercialization of potential products, regulatory approvals, need
and ability to obtain future capital, application of capital
resources among competing uses, and maintenance of intellectual
property rights. Actual results may differ materially from the
results anticipated in these forward-looking statements and as such
should be evaluated together with the many uncertainties that
affect the company's business, particularly those mentioned in the
cautionary statements found in the company's Securities and
Exchange Commission filings. The company disclaims any intent or
obligation to update forward-looking
statements.
International Stem Cell Corporation
Contact
Dr. Russell Kern
EVP, Chief Scientific Officer
(760) 940-6383
ir@intlstemcell.com
International Stem Cell (QB) (USOTC:ISCO)
Historical Stock Chart
From Apr 2024 to May 2024
International Stem Cell (QB) (USOTC:ISCO)
Historical Stock Chart
From May 2023 to May 2024